person · Reporting owner

VITULLO NICOLE

Disclosed activity across 10 companies

Tapewire entity: 79004
SEC CIK: 0001196863

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Adynxx, Inc.ADYX · Entity 155807	10% owner	May 03, 2019	May 13, 2019
Bionano Genomics, Inc.BNGO · Entity 7831	10% owner	August 23, 2018	August 27, 2018
Esperion Therapeutics, Inc.ESPR · Entity 30796	Director	May 29, 2025	June 02, 2025
MARINUS PHARMACEUTICALS, INC.MRNS · Entity 83359	Director	February 04, 2022	February 07, 2022
Vyome Holdings, IncOBLN · Entity 1824	10% owner	August 06, 2019	August 08, 2019

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Adynxx, Inc.

Report date May 03, 2019 · Filed May 13, 2019

Jointly reported with DP VIII Associates, L.P., BLAIR JAMES C, TREU JESSE I, DOVEY BRIAN H, Halak Brian K

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	22,527	Reported balance Holding disclosure · report date 2019-05-03 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 22,527 F1: The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of One Partner Square Associates VIII, LLC, the sole general partner of the designated Reporting Person. Pursuant to Instruction 5(b)(iv) of Form 3, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her.

Filing footnotes · ownership attribution and instrument terms

F1: The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of One Partner Square Associates VIII, LLC, the sole general partner of the designated Reporting Person. Pursuant to Instruction 5(b)(iv) of Form 3, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her.

Bionano Genomics, Inc.

Report date August 23, 2018 · Filed August 27, 2018

Jointly reported with DP VIII Associates, L.P., BLAIR JAMES C, DOVEY BRIAN H, TREU JESSE I, Halak Brian K

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	6,891	Last balance in matching sequence After 2018-08-23 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 1 · 2018-08-23 · Conversion · Acquired 4,386 · Balance 4,386 F1: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The Preferred Stock had no expiration date F2: The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of One Partner Square Associates VIII, LLC, the sole general partner of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her. Row 2 · 2018-08-23 · Conversion · Acquired 2,505 · Balance 6,891 F3: The principal amount of the Convertible Promissory Note held by the designated Reporting Person was $11,048. Upon closing of the IPO, all unpaid principal and accrued interest outstanding on the Convertible Promissory Note (the "Conversion Amount") automatically converted into the number of shares of Common Stock equal to the Conversion Amount as of the date immediately prior to the closing date divided by 75% of the IPO price per share of $6.125 per share. F2: The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of One Partner Square Associates VIII, LLC, the sole general partner of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her.
Series B Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2018-08-23 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2018-08-23 · Conversion · Disposed 50,532 · Balance 0 F1: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The Preferred Stock had no expiration date F2: The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of One Partner Square Associates VIII, LLC, the sole general partner of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her.
Series B-1 Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2018-08-23 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2018-08-23 · Conversion · Disposed 22,161 · Balance 0 F1: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The Preferred Stock had no expiration date F2: The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of One Partner Square Associates VIII, LLC, the sole general partner of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her.
Series C Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2018-08-23 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2018-08-23 · Conversion · Disposed 40,268 · Balance 0 F1: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The Preferred Stock had no expiration date F2: The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of One Partner Square Associates VIII, LLC, the sole general partner of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her.
Series D Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2018-08-23 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2018-08-23 · Conversion · Disposed 47,460 · Balance 0 F1: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The Preferred Stock had no expiration date F2: The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of One Partner Square Associates VIII, LLC, the sole general partner of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her.
Series D-1 Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2018-08-23 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2018-08-23 · Conversion · Disposed 27,328 · Balance 0 F1: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The Preferred Stock had no expiration date F2: The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of One Partner Square Associates VIII, LLC, the sole general partner of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her.
Convertible Promissory NoteSEC Table II · derivative / convertible security · Conversion / exercise price $4.59	Direct	0	Reported balance After 2018-08-23 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2018-08-23 · Conversion · Disposed Not disclosed · Balance 0 F3: The principal amount of the Convertible Promissory Note held by the designated Reporting Person was $11,048. Upon closing of the IPO, all unpaid principal and accrued interest outstanding on the Convertible Promissory Note (the "Conversion Amount") automatically converted into the number of shares of Common Stock equal to the Conversion Amount as of the date immediately prior to the closing date divided by 75% of the IPO price per share of $6.125 per share. F2: The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of One Partner Square Associates VIII, LLC, the sole general partner of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her.

Filing footnotes · ownership attribution and instrument terms

F1: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The Preferred Stock had no expiration date

F2: The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of One Partner Square Associates VIII, LLC, the sole general partner of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her.

F3: The principal amount of the Convertible Promissory Note held by the designated Reporting Person was $11,048. Upon closing of the IPO, all unpaid principal and accrued interest outstanding on the Convertible Promissory Note (the "Conversion Amount") automatically converted into the number of shares of Common Stock equal to the Conversion Amount as of the date immediately prior to the closing date divided by 75% of the IPO price per share of $6.125 per share.

Esperion Therapeutics, Inc.

Report date May 29, 2025 · Filed June 02, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.87 · Expires 2035-05-29	Direct	88,000	Reported balance After 2025-05-29 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2025-05-29 · Grant · Acquired 88,000 · Balance 88,000 F1: The awards vest in full on the earlier of (i) May 29, 2026 and (ii) the Issuer's next annual meeting of stockholders following May 29, 2025.

Filing footnotes · ownership attribution and instrument terms

F1: The awards vest in full on the earlier of (i) May 29, 2026 and (ii) the Issuer's next annual meeting of stockholders following May 29, 2025.

MARINUS PHARMACEUTICALS, INC.

Report date February 04, 2022 · Filed February 07, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	6,442	Reported balance After 2022-02-04 transaction · row 1 1 source row Row 1 · 2022-02-04 · Grant · Acquired 2,750 · Balance 6,442 F1: Represents the grant of restricted stock units (RSUs). The RSUs vest in full on February 4, 2023, subject to the reporting person's continued service with Marinus Pharmaceuticals, Inc. (the Issuer). Each RSU represents the right to receive one share of common stock of the Issuer.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.40 · Expires 2032-02-04	Direct	12,375	Reported balance After 2022-02-04 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2022-02-04 · Grant · Acquired 12,375 · Balance 12,375 F2: The option vests and becomes exercisable in 12 equal monthly installments beginning on March 4, 2022.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the grant of restricted stock units (RSUs). The RSUs vest in full on February 4, 2023, subject to the reporting person's continued service with Marinus Pharmaceuticals, Inc. (the Issuer). Each RSU represents the right to receive one share of common stock of the Issuer.

F2: The option vests and becomes exercisable in 12 equal monthly installments beginning on March 4, 2022.

Vyome Holdings, Inc

Report date August 06, 2019 · Filed August 08, 2019

Jointly reported with DOMAIN PARTERS VII L P, BLAIR JAMES C, DOVEY BRIAN H, TREU JESSE I, Halak Brian K

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	813,433	Reported balance After 2019-08-06 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2019-08-06 · Purchase · Acquired 250,000 · Balance 813,433 F1: The reported securities were purchased as Units, each Unit consisting of one share of Common Stock and a Warrant to purchase 0.75 of one share of Common Stock, at a purchase price of $4.00 per Unit. F2: The reported ownership reflects the one-for-ten reverse split of the Common Stock effected on July 24, 2019. F3: The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of One Palmer Square Associates VII, LLC, the sole general partner of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her. F4: As managing members of One Palmer Square Associates VII, LLC, which is also the sole general partner of DP VII Associates, L.P., each Reporting Owner listed below may also be deemed to indirectly beneficially own 4,957 shares of Common Stock held by DP VII Associates, L.P.
Warrants to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $4.40 · Expires 2024-08-06	Direct	187,500	Reported balance After 2019-08-06 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2019-08-06 · Purchase · Acquired 187,500 · Balance 187,500 F1: The reported securities were purchased as Units, each Unit consisting of one share of Common Stock and a Warrant to purchase 0.75 of one share of Common Stock, at a purchase price of $4.00 per Unit. F3: The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of One Palmer Square Associates VII, LLC, the sole general partner of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her.

Filing footnotes · ownership attribution and instrument terms

F1: The reported securities were purchased as Units, each Unit consisting of one share of Common Stock and a Warrant to purchase 0.75 of one share of Common Stock, at a purchase price of $4.00 per Unit.

F2: The reported ownership reflects the one-for-ten reverse split of the Common Stock effected on July 24, 2019.

F3: The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of One Palmer Square Associates VII, LLC, the sole general partner of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her.

F4: As managing members of One Palmer Square Associates VII, LLC, which is also the sole general partner of DP VII Associates, L.P., each Reporting Owner listed below may also be deemed to indirectly beneficially own 4,957 shares of Common Stock held by DP VII Associates, L.P.

Past disclosures · reporting ended (5)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ACHILLION PHARMACEUTICALS INC

Report date January 28, 2020 · Filed January 29, 2020

Section 16 reporting ended · disclosed 2020-01-29. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2020-01-28 transaction · row 1 1 source row Row 1 · 2020-01-28 · Disposition to issuer · Disposed 36,431 · Balance 0 F1: Disposed of pursuant to the merger agreement (the "Merger Agreement") among Achillion Pharmaceuticals, Inc. ("Achillion"), Alexion Pharmaceuticals, Inc. ("Alexion") and Beagle Merger Sub, Inc. In addition to the cash consideration of $6.30 per share, each shareholder will also receive one contingent value right ("CVR") per share. Each CVR represents the right to receive contingent cash payments of $1.00 upon the achievement of a certain clinical trial milestone with respect to ACH-5228 and $1.00 upon the achievement of a certain regulatory approval milestone with respect to ACH-4471.
Common StockSEC Table I · non-derivative	IndirectBy Domain Partners VIII, L.P.	Reported balance After 2020-01-28 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2020-01-28 · Disposition to issuer · Disposed 3,393,382 · Balance 0 F1: Disposed of pursuant to the merger agreement (the "Merger Agreement") among Achillion Pharmaceuticals, Inc. ("Achillion"), Alexion Pharmaceuticals, Inc. ("Alexion") and Beagle Merger Sub, Inc. In addition to the cash consideration of $6.30 per share, each shareholder will also receive one contingent value right ("CVR") per share. Each CVR represents the right to receive contingent cash payments of $1.00 upon the achievement of a certain clinical trial milestone with respect to ACH-5228 and $1.00 upon the achievement of a certain regulatory approval milestone with respect to ACH-4471. F2: The Reporting Person is a Managing Member of Domain Associates, LLC and a Managing Member of One Palmer Square Associates VIII, LLC, which is the sole general partner of Domain Partners VIII, L.P. and DP VIII Associates, L.P. Pursuant to Instruction 4(b)(iv) of Form 4, the Reporting Person has elected to report as indirectly beneficially owned the entire number of securities beneficially owned by each such entity. The Reporting Person disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed her pecuniary interest therein and/or that are not actually distributed to her.
Common StockSEC Table I · non-derivative	IndirectBy DP VIII Associates, L.P.	Reported balance After 2020-01-28 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2020-01-28 · Disposition to issuer · Disposed 25,159 · Balance 0 F1: Disposed of pursuant to the merger agreement (the "Merger Agreement") among Achillion Pharmaceuticals, Inc. ("Achillion"), Alexion Pharmaceuticals, Inc. ("Alexion") and Beagle Merger Sub, Inc. In addition to the cash consideration of $6.30 per share, each shareholder will also receive one contingent value right ("CVR") per share. Each CVR represents the right to receive contingent cash payments of $1.00 upon the achievement of a certain clinical trial milestone with respect to ACH-5228 and $1.00 upon the achievement of a certain regulatory approval milestone with respect to ACH-4471. F2: The Reporting Person is a Managing Member of Domain Associates, LLC and a Managing Member of One Palmer Square Associates VIII, LLC, which is the sole general partner of Domain Partners VIII, L.P. and DP VIII Associates, L.P. Pursuant to Instruction 4(b)(iv) of Form 4, the Reporting Person has elected to report as indirectly beneficially owned the entire number of securities beneficially owned by each such entity. The Reporting Person disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed her pecuniary interest therein and/or that are not actually distributed to her.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.10 · Expires 2020-12-16	Direct	Reported balance After 2020-01-28 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-01-28 · Disposition to issuer · Disposed 50,000 · Balance 0 F3: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.59 · Expires 2021-12-12	Direct	Reported balance After 2020-01-28 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-01-28 · Disposition to issuer · Disposed 20,000 · Balance 0 F3: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.64 · Expires 2022-12-18	Direct	Reported balance After 2020-01-28 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2020-01-28 · Disposition to issuer · Disposed 20,000 · Balance 0 F3: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.02 · Expires 2023-12-17	Direct	Reported balance After 2020-01-28 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2020-01-28 · Disposition to issuer · Disposed 25,000 · Balance 0 F3: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.24 · Expires 2024-12-02	Direct	Reported balance After 2020-01-28 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2020-01-28 · Disposition to issuer · Disposed 25,000 · Balance 0 F3: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.54 · Expires 2026-01-25	Direct	Reported balance After 2020-01-28 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2020-01-28 · Disposition to issuer · Disposed 30,000 · Balance 0 F3: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.09 · Expires 2027-01-19	Direct	Reported balance After 2020-01-28 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2020-01-28 · Disposition to issuer · Disposed 30,000 · Balance 0 F3: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.90 · Expires 2028-02-09	Direct	Reported balance After 2020-01-28 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2020-01-28 · Disposition to issuer · Disposed 30,000 · Balance 0 F3: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.18 · Expires 2029-01-23	Direct	Reported balance After 2020-01-28 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2020-01-28 · Disposition to issuer · Disposed 42,000 · Balance 0 F3: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to the merger agreement (the "Merger Agreement") among Achillion Pharmaceuticals, Inc. ("Achillion"), Alexion Pharmaceuticals, Inc. ("Alexion") and Beagle Merger Sub, Inc. In addition to the cash consideration of $6.30 per share, each shareholder will also receive one contingent value right ("CVR") per share. Each CVR represents the right to receive contingent cash payments of $1.00 upon the achievement of a certain clinical trial milestone with respect to ACH-5228 and $1.00 upon the achievement of a certain regulatory approval milestone with respect to ACH-4471.

F2: The Reporting Person is a Managing Member of Domain Associates, LLC and a Managing Member of One Palmer Square Associates VIII, LLC, which is the sole general partner of Domain Partners VIII, L.P. and DP VIII Associates, L.P. Pursuant to Instruction 4(b)(iv) of Form 4, the Reporting Person has elected to report as indirectly beneficially owned the entire number of securities beneficially owned by each such entity. The Reporting Person disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed her pecuniary interest therein and/or that are not actually distributed to her.

F3: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor.

CoLucid Pharmaceuticals, Inc.

Report date September 09, 2016 · Filed September 13, 2016

Jointly reported with Domain Partners VI, L.P., BLAIR JAMES C, DOVEY BRIAN H, TREU JESSE I

Section 16 reporting ended · disclosed 2016-09-13. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2016-09-09 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2016-09-09 · Other · Disposed 1,943,109 · Balance 0 F1: Distribution of shares in kind by Domain Partners VI, L.P. to its partners. F2: The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of the sole general partner of Domain Partners VI, L.P. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by Domain Partners VI, L.P., however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein, and/or that are not actually distributed to him or her.

Filing footnotes · ownership attribution and instrument terms

F1: Distribution of shares in kind by Domain Partners VI, L.P. to its partners.

F2: The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of the sole general partner of Domain Partners VI, L.P. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by Domain Partners VI, L.P., however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein, and/or that are not actually distributed to him or her.

Dicerna Pharmaceuticals Inc

Report date December 18, 2017 · Filed December 20, 2017

Jointly reported with DP VIII Associates, L.P., BLAIR JAMES C, DOVEY BRIAN H, TREU JESSE I, Halak Brian K

Section 16 reporting ended · disclosed 2017-12-20. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	25,730	Last balance in matching sequence After 2017-12-18 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 1 · 2017-12-18 · Conversion · Acquired 12,444 · Balance 25,448 F3: The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of One Palmer Square Associates VIII, LLC, the sole general partner of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her. Row 2 · 2017-12-18 · Grant · Acquired 282 · Balance 25,730 F4: The Reporting Person received an additional 282 shares of Common Stock from the Issuer, representing the additional dividend accruals on the Redeemable Convertible Preferred Stock that the Reporting Person would have been entitled to receive up to and including March 31, 2018. F3: The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of One Palmer Square Associates VIII, LLC, the sole general partner of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her.
Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $3.19	Direct	0	Reported balance After 2017-12-18 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2017-12-18 · Conversion · Disposed 368 · Balance 0 F1: The Redeemable Convertible Preferred Stock was immediately convertible upon its purchase on 04/11/2017, subject to certain conditions. The Redeemable Convertible Preferred Stock had no expiration date. F2: Each share of Redeemable Convertible Preferred Stock had a stated value of $100 (the "Stated Value") and accrued dividends daily at an initial rate of 12% per annum, which was reduced to 8% per annum on October 28, 2017 in accordance with the Certificate of Designations for the Redeemable Convertible Preferred Stock. The Stated Value, as adjusted to give effect to such dividends, was referred to as the "Accrued Value." Each share of Redeemable Convertible Preferred Stock was convertible, at the option of the holder or, upon the occurrence of certain events, at the option of the Issuer, and subject to certain conditions, into a number of shares of Common Stock determined by dividing the Accrued Value by the conversion price. F3: The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of One Palmer Square Associates VIII, LLC, the sole general partner of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her.

Filing footnotes · ownership attribution and instrument terms

F1: The Redeemable Convertible Preferred Stock was immediately convertible upon its purchase on 04/11/2017, subject to certain conditions. The Redeemable Convertible Preferred Stock had no expiration date.

F2: Each share of Redeemable Convertible Preferred Stock had a stated value of $100 (the "Stated Value") and accrued dividends daily at an initial rate of 12% per annum, which was reduced to 8% per annum on October 28, 2017 in accordance with the Certificate of Designations for the Redeemable Convertible Preferred Stock. The Stated Value, as adjusted to give effect to such dividends, was referred to as the "Accrued Value." Each share of Redeemable Convertible Preferred Stock was convertible, at the option of the holder or, upon the occurrence of certain events, at the option of the Issuer, and subject to certain conditions, into a number of shares of Common Stock determined by dividing the Accrued Value by the conversion price.

F3: The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of One Palmer Square Associates VIII, LLC, the sole general partner of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her.

F4: The Reporting Person received an additional 282 shares of Common Stock from the Issuer, representing the additional dividend accruals on the Redeemable Convertible Preferred Stock that the Reporting Person would have been entitled to receive up to and including March 31, 2018.

Ocera Therapeutics, Inc.

Report date December 11, 2017 · Filed December 13, 2017

Jointly reported with DOMAIN ASSOCIATES, BLAIR JAMES C, DOVEY BRIAN H, TREU JESSE I, Halak Brian K, Kamdar Kim P.

Section 16 reporting ended · disclosed 2017-12-13. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2017-12-11 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2017-12-11 · Disposition to issuer · Disposed 47,963 · Balance 0 F1: Pursuant to an Agreement and Plan of Merger, dated November 1, 2017 (the "Merger Agreement"), by and between the Issuer, MAK LLC, a Delaware limited liability company ("Parent"), MEH Acquisition Co., a Delaware corporation and a direct wholly-owned subsidiary of Parent ("Purchaser"), and for limited purposes, Mallinckrodt plc, an Irish public limited company and the ultimate parent entity of Parent and Purchaser ("Mallinckrodt"), Purchaser was merged with and into the Issuer on December 11, 2017, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). F2: (Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, all shares Common Stock of the Issuer outstanding immediately prior to the effective time of the Merger were canceled and converted automatically into the right to receive (i) $1.52 per share in cash, plus (ii) one non-transferable contingent value right per Share (each, a "CVR"), which represents the contractual right under a contingent value rights agreement, by and among Parent, Continental Stock Transfer & Trust Company, and for limited purposes, Mallinckrodt, entered into on December 7, 2017, to receive one or more payments in cash currently estimated to be up to $2.58 per share, contingent upon the achievement of certain milestones, in each case, less any required withholding taxes. F3: The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to an Agreement and Plan of Merger, dated November 1, 2017 (the "Merger Agreement"), by and between the Issuer, MAK LLC, a Delaware limited liability company ("Parent"), MEH Acquisition Co., a Delaware corporation and a direct wholly-owned subsidiary of Parent ("Purchaser"), and for limited purposes, Mallinckrodt plc, an Irish public limited company and the ultimate parent entity of Parent and Purchaser ("Mallinckrodt"), Purchaser was merged with and into the Issuer on December 11, 2017, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger").

F2: (Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, all shares Common Stock of the Issuer outstanding immediately prior to the effective time of the Merger were canceled and converted automatically into the right to receive (i) $1.52 per share in cash, plus (ii) one non-transferable contingent value right per Share (each, a "CVR"), which represents the contractual right under a contingent value rights agreement, by and among Parent, Continental Stock Transfer & Trust Company, and for limited purposes, Mallinckrodt, entered into on December 7, 2017, to receive one or more payments in cash currently estimated to be up to $2.58 per share, contingent upon the achievement of certain milestones, in each case, less any required withholding taxes.

F3: The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her.

Tobira Therapeutics, Inc.

Report date November 01, 2016 · Filed November 04, 2016

Jointly reported with DOMAIN ASSOCIATES, BLAIR JAMES C, DOVEY BRIAN H, TREU JESSE I, Halak Brian K, Kamdar Kim P.

Section 16 reporting ended · disclosed 2016-11-04. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2016-11-01 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2016-11-01 · Other · Disposed 38,094 · Balance 0 F1: Pursuant to the terms of a merger agreement, pursuant to which the Issuer was acquired by Allergan Holdco US, Inc., the shares were tendered for $28.35 per share in cash plus one non-transferable contingent value right per share, which represents the contractual right to receive one or more payments in cash of up to $49.84 per share in the aggregate, contingent upon the achievement of certain milestones. F2: The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly benefically owned by each of the Reporting Owners listed below, each of whom is a managing member of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.00	IndirectHeld by Jesse I. Treu	Reported balance After 2016-11-01 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2016-11-01 · Disposition to issuer · Acquired 1,996 · Balance 0 F3: Pursuant to the terms of the merger described above, each outstanding option to purchase Common Stock which had an exercise price less than $28.35 per share was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) $28.35 over (y) the exercise price per share, multiplied by (B) the total number of shares subject to such option immediately prior to the effective time of the merger and (ii) a contingent value right with respect to the total number of shares subject to such option immediately prior to the effective time of the merger. F4: Each other outstanding option to purchase Common Stock was cancelled and converted into the right to receive a cash payment, if any, from Allergan Holdco US, Inc. with respect to each share subject to such option upon each date that a payment would be required to a holder of a contingent value right under the terms of the contingent value rights agreement that was entered into in connection with the merger agreement on or prior to the fifth anniversary of the effective time of the merger.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.93	IndirectHeld by Jesse I. Treu	Reported balance After 2016-11-01 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2016-11-01 · Disposition to issuer · Acquired 1,071 · Balance 0 F3: Pursuant to the terms of the merger described above, each outstanding option to purchase Common Stock which had an exercise price less than $28.35 per share was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) $28.35 over (y) the exercise price per share, multiplied by (B) the total number of shares subject to such option immediately prior to the effective time of the merger and (ii) a contingent value right with respect to the total number of shares subject to such option immediately prior to the effective time of the merger. F4: Each other outstanding option to purchase Common Stock was cancelled and converted into the right to receive a cash payment, if any, from Allergan Holdco US, Inc. with respect to each share subject to such option upon each date that a payment would be required to a holder of a contingent value right under the terms of the contingent value rights agreement that was entered into in connection with the merger agreement on or prior to the fifth anniversary of the effective time of the merger.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.19	IndirectHeld by Jesse I. Treu	Reported balance After 2016-11-01 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2016-11-01 · Disposition to issuer · Acquired 17,695 · Balance 0 F3: Pursuant to the terms of the merger described above, each outstanding option to purchase Common Stock which had an exercise price less than $28.35 per share was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) $28.35 over (y) the exercise price per share, multiplied by (B) the total number of shares subject to such option immediately prior to the effective time of the merger and (ii) a contingent value right with respect to the total number of shares subject to such option immediately prior to the effective time of the merger. F4: Each other outstanding option to purchase Common Stock was cancelled and converted into the right to receive a cash payment, if any, from Allergan Holdco US, Inc. with respect to each share subject to such option upon each date that a payment would be required to a holder of a contingent value right under the terms of the contingent value rights agreement that was entered into in connection with the merger agreement on or prior to the fifth anniversary of the effective time of the merger.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the terms of a merger agreement, pursuant to which the Issuer was acquired by Allergan Holdco US, Inc., the shares were tendered for $28.35 per share in cash plus one non-transferable contingent value right per share, which represents the contractual right to receive one or more payments in cash of up to $49.84 per share in the aggregate, contingent upon the achievement of certain milestones.

F2: The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly benefically owned by each of the Reporting Owners listed below, each of whom is a managing member of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her.

F3: Pursuant to the terms of the merger described above, each outstanding option to purchase Common Stock which had an exercise price less than $28.35 per share was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) $28.35 over (y) the exercise price per share, multiplied by (B) the total number of shares subject to such option immediately prior to the effective time of the merger and (ii) a contingent value right with respect to the total number of shares subject to such option immediately prior to the effective time of the merger.

F4: Each other outstanding option to purchase Common Stock was cancelled and converted into the right to receive a cash payment, if any, from Allergan Holdco US, Inc. with respect to each share subject to such option upon each date that a payment would be required to a holder of a contingent value right under the terms of the contingent value rights agreement that was entered into in connection with the merger agreement on or prior to the fifth anniversary of the effective time of the merger.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 29, 2025 Filed Jun 2, 2025 20:07 UTC	Esperion Therapeutics, Inc. ESPR · Entity 30796	GrantStock Option (right to buy) · Derivative	88,000	$0.00 Strike: $0.87	$0.00	Disclosure SEC source: 0001628280-25-028822 · wk-form4_1748894817.xml · derivative · entry 1 VITULLO NICOLE · CIK 0001196863 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,000 Underlying: Common Stock · 88,000 shares Expires 2035-05-29 F1 · derivative.exercise_date: The awards vest in full on the earlier of (i) May 29, 2026 and (ii) the Issuer's next annual meeting of stockholders following May 29, 2025. Read SEC document
May 23, 2024 Filed May 24, 2024 20:13 UTC	Esperion Therapeutics, Inc. ESPR · Entity 30796	GrantStock Option (right to buy) · Derivative	65,000	$0.00 Strike: $2.25	$0.00	Disclosure SEC source: 0001628280-24-025206 · wk-form4_1716581610.xml · derivative · entry 1 VITULLO NICOLE · CIK 0001196863 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2034-05-23 F1 · derivative.exercise_date: The awards vest in full on the earlier of (i) May 23, 2025 and (ii) the Issuer's next annual meeting of stockholders following May 23, 2024. Read SEC document
June 15, 2023 Filed Jun 16, 2023 20:07 UTC	Esperion Therapeutics, Inc. ESPR · Entity 30796	GrantStock Option (right to buy) · Derivative	21,000	$0.00 Strike: $1.37	$0.00	Disclosure SEC source: 0001628280-23-022455 · wf-form4_168694602658326.xml · derivative · entry 2 VITULLO NICOLE · CIK 0001196863 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires 2033-06-15 F1 · derivative.exercise_date: The awards vest in full on the earlier of (i) June 15, 2024 and (ii) the Issuer's next annual meeting of stockholders following June 15, 2023. Read SEC document
June 15, 2023 Filed Jun 16, 2023 20:07 UTC	Esperion Therapeutics, Inc. ESPR · Entity 30796	GrantCommon Stock	5,150	$0.00	$0.00	Disclosure SEC source: 0001628280-23-022455 · wf-form4_168694602658326.xml · nonDerivative · entry 1 VITULLO NICOLE · CIK 0001196863 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,918 F1 · shares: The awards vest in full on the earlier of (i) June 15, 2024 and (ii) the Issuer's next annual meeting of stockholders following June 15, 2023. Read SEC document
May 26, 2022 Filed May 27, 2022 20:18 UTC	Esperion Therapeutics, Inc. ESPR · Entity 30796	GrantStock Option (right to buy) · Derivative	20,000	$0.00 Strike: $5.51	$0.00	Disclosure SEC source: 0001628280-22-015589 · wf-form4_165368265462041.xml · derivative · entry 1 VITULLO NICOLE · CIK 0001196863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-05-26 F1 · derivative.exercise_date: The awards vest in full on the earlier of (i) May 26, 2023 and (ii) the Issuer's next annual meeting of stockholders following May 26, 2022. Read SEC document
February 04, 2022 Filed Feb 7, 2022 16:14 UTC	MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359	GrantStock Option (Right to Buy) · Derivative	12,375	$0.00 Strike: $10.40	$0.00	Disclosure SEC source: 0001104659-22-012796 · tm225605-12_4seq1.xml · derivative · entry 2 VITULLO NICOLE · CIK 0001196863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,375 Underlying: Common Stock · 12,375 shares Expires 2032-02-04 F2 · derivative.exercise_date: The option vests and becomes exercisable in 12 equal monthly installments beginning on March 4, 2022. Read SEC document
February 04, 2022 Filed Feb 7, 2022 16:14 UTC	MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359	GrantCommon Stock	2,750	$0.00	$0.00	Disclosure SEC source: 0001104659-22-012796 · tm225605-12_4seq1.xml · nonDerivative · entry 1 VITULLO NICOLE · CIK 0001196863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,442 F1 · shares: Represents the grant of restricted stock units (RSUs). The RSUs vest in full on February 4, 2023, subject to the reporting person's continued service with Marinus Pharmaceuticals, Inc. (the Issuer). Each RSU represents the right to receive one share of common stock of the Issuer. Read SEC document
May 27, 2021 Filed May 28, 2021 20:17 UTC	Esperion Therapeutics, Inc. ESPR · Entity 30796	GrantCommon Stock	12,376	$0.00	$0.00	Disclosure SEC source: 0001628280-21-011357 · wf-form4_162223302655299.xml · nonDerivative · entry 1 VITULLO NICOLE · CIK 0001196863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,768 F1 · shares: The shares vest in full on the earlier of (i) May 27, 2022 and (ii) the Issuer's next annual meeting of stockholders following May 27, 2021. Read SEC document
March 16, 2021 Filed Mar 16, 2021 16:58 UTC	MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359	OtherCommon Stock	2,717	$0.00	$0.00	Disclosure SEC source: 0000904454-21-000348 · edgar.xml · nonDerivative · entry 6 VITULLO NICOLE · CIK 0001196863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,692 F4 · kind: Distribution of shares by One Palmer Square Associates VI, L.P. pro rata to its partners. F5 · kind: Distribution of shares by Domain Associates, LLC pro rata to its members. F4 · price: Distribution of shares by One Palmer Square Associates VI, L.P. pro rata to its partners. F5 · price: Distribution of shares by Domain Associates, LLC pro rata to its members. Read SEC document
March 16, 2021 Filed Mar 16, 2021 16:58 UTC	MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359	OtherCommon Stock	11,612	$0.00	$0.00	Disclosure SEC source: 0000904454-21-000348 · edgar.xml · nonDerivative · entry 5 VITULLO NICOLE · CIK 0001196863 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Domain Associates, LLC Disclosed balance after: 0 F5 · kind: Distribution of shares by Domain Associates, LLC pro rata to its members. F5 · price: Distribution of shares by Domain Associates, LLC pro rata to its members. F2 · ownership.nature: The Reporting Person is a managing member of One Palmer Square Associates VI, LLC, the sole general partner of Domain Partners VI, L.P. and DP VI Associates, L.P., and of Domain Associates, LLC. Pursuant to Instruction 4(b)(iv) of Form 4, the Reporting Person has elected to report as indirectly beneficially owned the entire number of securities owned by each such entity, however she disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed her pecuniary interest therein and/or that are not actually distributed to her. Read SEC document
March 16, 2021 Filed Mar 16, 2021 16:58 UTC	MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359	OtherCommon Stock	6,192	$0.00	$0.00	Disclosure SEC source: 0000904454-21-000348 · edgar.xml · nonDerivative · entry 4 VITULLO NICOLE · CIK 0001196863 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By One Palmer Square Associates VI, LLC Disclosed balance after: 0 F4 · kind: Distribution of shares by One Palmer Square Associates VI, L.P. pro rata to its partners. F4 · price: Distribution of shares by One Palmer Square Associates VI, L.P. pro rata to its partners. F2 · ownership.nature: The Reporting Person is a managing member of One Palmer Square Associates VI, LLC, the sole general partner of Domain Partners VI, L.P. and DP VI Associates, L.P., and of Domain Associates, LLC. Pursuant to Instruction 4(b)(iv) of Form 4, the Reporting Person has elected to report as indirectly beneficially owned the entire number of securities owned by each such entity, however she disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed her pecuniary interest therein and/or that are not actually distributed to her. Read SEC document
March 15, 2021 Filed Mar 16, 2021 16:58 UTC	MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359	SaleCommon Stock	4,250	$15.87	$67,447.50	Disclosure SEC source: 0000904454-21-000348 · edgar.xml · nonDerivative · entry 3 VITULLO NICOLE · CIK 0001196863 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By DP VI Associates, L.P. Disclosed balance after: 0 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.61 to $16.25. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2 · ownership.nature: The Reporting Person is a managing member of One Palmer Square Associates VI, LLC, the sole general partner of Domain Partners VI, L.P. and DP VI Associates, L.P., and of Domain Associates, LLC. Pursuant to Instruction 4(b)(iv) of Form 4, the Reporting Person has elected to report as indirectly beneficially owned the entire number of securities owned by each such entity, however she disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed her pecuniary interest therein and/or that are not actually distributed to her. Read SEC document
March 12, 2021 Filed Mar 16, 2021 16:58 UTC	MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359	OtherCommon Stock	6,192	$0.00	$0.00	Disclosure SEC source: 0000904454-21-000348 · edgar.xml · nonDerivative · entry 2 VITULLO NICOLE · CIK 0001196863 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By One Palmer Square Associates VI, LLC Disclosed balance after: 6,192 F1 · kind: Distribution of shares by Domain Partners VI, L.P. pro rata to its partners. F1 · price: Distribution of shares by Domain Partners VI, L.P. pro rata to its partners. F2 · ownership.nature: The Reporting Person is a managing member of One Palmer Square Associates VI, LLC, the sole general partner of Domain Partners VI, L.P. and DP VI Associates, L.P., and of Domain Associates, LLC. Pursuant to Instruction 4(b)(iv) of Form 4, the Reporting Person has elected to report as indirectly beneficially owned the entire number of securities owned by each such entity, however she disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed her pecuniary interest therein and/or that are not actually distributed to her. Read SEC document
March 12, 2021 Filed Mar 16, 2021 16:58 UTC	MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359	OtherCommon Stock	619,221	$0.00	$0.00	Disclosure SEC source: 0000904454-21-000348 · edgar.xml · nonDerivative · entry 1 VITULLO NICOLE · CIK 0001196863 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Domain Partners VI, L.P. Disclosed balance after: 0 F1 · kind: Distribution of shares by Domain Partners VI, L.P. pro rata to its partners. F1 · price: Distribution of shares by Domain Partners VI, L.P. pro rata to its partners. F2 · ownership.nature: The Reporting Person is a managing member of One Palmer Square Associates VI, LLC, the sole general partner of Domain Partners VI, L.P. and DP VI Associates, L.P., and of Domain Associates, LLC. Pursuant to Instruction 4(b)(iv) of Form 4, the Reporting Person has elected to report as indirectly beneficially owned the entire number of securities owned by each such entity, however she disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed her pecuniary interest therein and/or that are not actually distributed to her. Read SEC document
January 15, 2021 Filed Jan 20, 2021 16:39 UTC	MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359	GrantStock Option (Right to Buy) · Derivative	16,500	$0.00 Strike: $12.60	$0.00	Disclosure SEC source: 0000904454-21-000034 · edgar.xml · derivative · entry 1 VITULLO NICOLE · CIK 0001196863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2031-01-15 F1 · derivative.exercise_date: The option vests monthly over 12 months beginning on January 31, 2021. Read SEC document
May 28, 2020 Filed May 29, 2020 20:38 UTC	Esperion Therapeutics, Inc. ESPR · Entity 30796	GrantCommon Stock	6,106	$0.00	$0.00	Disclosure SEC source: 0001179110-20-006715 · edgar.xml · nonDerivative · entry 1 VITULLO NICOLE · CIK 0001196863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,392 F1 · shares: The shares vest in full on the earlier of (i) May 28, 2021 and (ii) the Issuer's next annual meeting of stockholders following May 28, 2020. Read SEC document
January 28, 2020 Filed Jan 29, 2020 17:30 UTC	ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234	Disposition to issuerStock Option (Right to Buy) · Derivative	42,000	Not disclosed Strike: $2.18	Not disclosed	Disclosure SEC source: 0000904454-20-000088 · edgar.xml · derivative · entry 12 VITULLO NICOLE · CIK 0001196863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 42,000 shares Expires 2029-01-23 F3 · price: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. F3 · derivative.exercise_date: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. Read SEC document
January 28, 2020 Filed Jan 29, 2020 17:30 UTC	ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234	Disposition to issuerStock Option (Right to Buy) · Derivative	30,000	Not disclosed Strike: $2.90	Not disclosed	Disclosure SEC source: 0000904454-20-000088 · edgar.xml · derivative · entry 11 VITULLO NICOLE · CIK 0001196863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2028-02-09 F3 · price: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. F3 · derivative.exercise_date: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. Read SEC document
January 28, 2020 Filed Jan 29, 2020 17:30 UTC	ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234	Disposition to issuerStock Option (Right to Buy) · Derivative	30,000	Not disclosed Strike: $4.09	Not disclosed	Disclosure SEC source: 0000904454-20-000088 · edgar.xml · derivative · entry 10 VITULLO NICOLE · CIK 0001196863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2027-01-19 F3 · price: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. F3 · derivative.exercise_date: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. Read SEC document
January 28, 2020 Filed Jan 29, 2020 17:30 UTC	ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234	Disposition to issuerStock Option (Right to Buy) · Derivative	30,000	Not disclosed Strike: $7.54	Not disclosed	Disclosure SEC source: 0000904454-20-000088 · edgar.xml · derivative · entry 9 VITULLO NICOLE · CIK 0001196863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2026-01-25 F3 · price: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. F3 · derivative.exercise_date: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. Read SEC document
January 28, 2020 Filed Jan 29, 2020 17:30 UTC	ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234	Disposition to issuerStock Option (Right to Buy) · Derivative	25,000	Not disclosed Strike: $13.24	Not disclosed	Disclosure SEC source: 0000904454-20-000088 · edgar.xml · derivative · entry 8 VITULLO NICOLE · CIK 0001196863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2024-12-02 F3 · price: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. F3 · derivative.exercise_date: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. Read SEC document
January 28, 2020 Filed Jan 29, 2020 17:30 UTC	ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234	Disposition to issuerStock Option (Right to Buy) · Derivative	25,000	Not disclosed Strike: $3.02	Not disclosed	Disclosure SEC source: 0000904454-20-000088 · edgar.xml · derivative · entry 7 VITULLO NICOLE · CIK 0001196863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2023-12-17 F3 · price: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. F3 · derivative.exercise_date: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. Read SEC document
January 28, 2020 Filed Jan 29, 2020 17:30 UTC	ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234	Disposition to issuerStock Option (Right to Buy) · Derivative	20,000	Not disclosed Strike: $8.64	Not disclosed	Disclosure SEC source: 0000904454-20-000088 · edgar.xml · derivative · entry 6 VITULLO NICOLE · CIK 0001196863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2022-12-18 F3 · price: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. F3 · derivative.exercise_date: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. Read SEC document
January 28, 2020 Filed Jan 29, 2020 17:30 UTC	ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234	Disposition to issuerStock Option (Right to Buy) · Derivative	20,000	Not disclosed Strike: $7.59	Not disclosed	Disclosure SEC source: 0000904454-20-000088 · edgar.xml · derivative · entry 5 VITULLO NICOLE · CIK 0001196863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2021-12-12 F3 · price: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. F3 · derivative.exercise_date: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. Read SEC document
January 28, 2020 Filed Jan 29, 2020 17:30 UTC	ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234	Disposition to issuerStock Option (Right to Buy) · Derivative	50,000	Not disclosed Strike: $3.10	Not disclosed	Disclosure SEC source: 0000904454-20-000088 · edgar.xml · derivative · entry 4 VITULLO NICOLE · CIK 0001196863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2020-12-16 F3 · price: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. F3 · derivative.exercise_date: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. Read SEC document
January 28, 2020 Filed Jan 29, 2020 17:30 UTC	ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234	Disposition to issuerCommon Stock	25,159	$6.30	$158,501.70	Disclosure SEC source: 0000904454-20-000088 · edgar.xml · nonDerivative · entry 3 VITULLO NICOLE · CIK 0001196863 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By DP VIII Associates, L.P. Disclosed balance after: 0 F1 · price: Disposed of pursuant to the merger agreement (the "Merger Agreement") among Achillion Pharmaceuticals, Inc. ("Achillion"), Alexion Pharmaceuticals, Inc. ("Alexion") and Beagle Merger Sub, Inc. In addition to the cash consideration of $6.30 per share, each shareholder will also receive one contingent value right ("CVR") per share. Each CVR represents the right to receive contingent cash payments of $1.00 upon the achievement of a certain clinical trial milestone with respect to ACH-5228 and $1.00 upon the achievement of a certain regulatory approval milestone with respect to ACH-4471. F2 · ownership.nature: The Reporting Person is a Managing Member of Domain Associates, LLC and a Managing Member of One Palmer Square Associates VIII, LLC, which is the sole general partner of Domain Partners VIII, L.P. and DP VIII Associates, L.P. Pursuant to Instruction 4(b)(iv) of Form 4, the Reporting Person has elected to report as indirectly beneficially owned the entire number of securities beneficially owned by each such entity. The Reporting Person disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed her pecuniary interest therein and/or that are not actually distributed to her. Read SEC document
January 28, 2020 Filed Jan 29, 2020 17:30 UTC	ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234	Disposition to issuerCommon Stock	3,393,382	$6.30	$21,378,306.60	Disclosure SEC source: 0000904454-20-000088 · edgar.xml · nonDerivative · entry 2 VITULLO NICOLE · CIK 0001196863 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Domain Partners VIII, L.P. Disclosed balance after: 0 F1 · price: Disposed of pursuant to the merger agreement (the "Merger Agreement") among Achillion Pharmaceuticals, Inc. ("Achillion"), Alexion Pharmaceuticals, Inc. ("Alexion") and Beagle Merger Sub, Inc. In addition to the cash consideration of $6.30 per share, each shareholder will also receive one contingent value right ("CVR") per share. Each CVR represents the right to receive contingent cash payments of $1.00 upon the achievement of a certain clinical trial milestone with respect to ACH-5228 and $1.00 upon the achievement of a certain regulatory approval milestone with respect to ACH-4471. F2 · ownership.nature: The Reporting Person is a Managing Member of Domain Associates, LLC and a Managing Member of One Palmer Square Associates VIII, LLC, which is the sole general partner of Domain Partners VIII, L.P. and DP VIII Associates, L.P. Pursuant to Instruction 4(b)(iv) of Form 4, the Reporting Person has elected to report as indirectly beneficially owned the entire number of securities beneficially owned by each such entity. The Reporting Person disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed her pecuniary interest therein and/or that are not actually distributed to her. Read SEC document
January 28, 2020 Filed Jan 29, 2020 17:30 UTC	ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234	Disposition to issuerCommon Stock	36,431	$6.30	$229,515.30	Disclosure SEC source: 0000904454-20-000088 · edgar.xml · nonDerivative · entry 1 VITULLO NICOLE · CIK 0001196863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Disposed of pursuant to the merger agreement (the "Merger Agreement") among Achillion Pharmaceuticals, Inc. ("Achillion"), Alexion Pharmaceuticals, Inc. ("Alexion") and Beagle Merger Sub, Inc. In addition to the cash consideration of $6.30 per share, each shareholder will also receive one contingent value right ("CVR") per share. Each CVR represents the right to receive contingent cash payments of $1.00 upon the achievement of a certain clinical trial milestone with respect to ACH-5228 and $1.00 upon the achievement of a certain regulatory approval milestone with respect to ACH-4471. Read SEC document
January 08, 2020 Filed Jan 10, 2020 16:48 UTC	MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359	GrantStock Option (Right to Buy) · Derivative	100,000	$0.00 Strike: $2.07	$0.00	Disclosure SEC source: 0000904454-20-000030 · edgar.xml · derivative · entry 1 VITULLO NICOLE · CIK 0001196863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-01-08 F1 · derivative.exercise_date: The option vests monthly over 12 months beginning on January 31, 2020. Read SEC document
January 08, 2020 Filed Nov 6, 2020 10:04 UTC Amendment	MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359	GrantStock Option (Right to Buy) · Derivative	150,000	$0.00 Strike: $2.07	$0.00	Disclosure SEC source: 0000904454-20-000703 · edgar.xml · derivative · entry 1 VITULLO NICOLE · CIK 0001196863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2030-01-08 F1 · derivative.exercise_price: On September 22, 2020 the Issuer effected a 1 for 4 reverse stock split, pursuant to which the exercise price was adjusted to $8.28 and the number of shares underlying the stock option was adjusted to 37,500. F1 · shares: On September 22, 2020 the Issuer effected a 1 for 4 reverse stock split, pursuant to which the exercise price was adjusted to $8.28 and the number of shares underlying the stock option was adjusted to 37,500. F2 · derivative.exercise_date: The option vests monthly over 12 months beginning on January 31, 2020. F1 · derivative.underlying_shares: On September 22, 2020 the Issuer effected a 1 for 4 reverse stock split, pursuant to which the exercise price was adjusted to $8.28 and the number of shares underlying the stock option was adjusted to 37,500. F1 · balance_after: On September 22, 2020 the Issuer effected a 1 for 4 reverse stock split, pursuant to which the exercise price was adjusted to $8.28 and the number of shares underlying the stock option was adjusted to 37,500. Read SEC document
August 06, 2019 Filed Aug 8, 2019 16:23 UTC	Vyome Holdings, Inc OBLN · Entity 1824	PurchaseWarrants to Purchase Common Stock · Derivative	187,500	$4.00 Strike: $4.40	$750,000.00	Disclosure SEC source: 0000904454-19-000600 · edgar.xml · derivative · entry 2 DOMAIN PARTERS VII L P · CIK 0001374150 · 10% owner BLAIR JAMES C · CIK 0001024000 · 10% owner DOVEY BRIAN H · CIK 0001207786 · 10% owner TREU JESSE I · CIK 0001013425 · 10% owner VITULLO NICOLE · CIK 0001196863 · 10% owner Halak Brian K · CIK 0001354718 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,500 Underlying: Common Stock · 187,500 shares Expires 2024-08-06 F1 · price: The reported securities were purchased as Units, each Unit consisting of one share of Common Stock and a Warrant to purchase 0.75 of one share of Common Stock, at a purchase price of $4.00 per Unit. F3 · ownership.direct: The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of One Palmer Square Associates VII, LLC, the sole general partner of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her. Read SEC document
August 06, 2019 Filed Aug 8, 2019 16:23 UTC	Vyome Holdings, Inc OBLN · Entity 1824	PurchaseCommon Stock	250,000	$4.00	$1,000,000.00	Disclosure SEC source: 0000904454-19-000600 · edgar.xml · nonDerivative · entry 1 DOMAIN PARTERS VII L P · CIK 0001374150 · 10% owner BLAIR JAMES C · CIK 0001024000 · 10% owner DOVEY BRIAN H · CIK 0001207786 · 10% owner TREU JESSE I · CIK 0001013425 · 10% owner VITULLO NICOLE · CIK 0001196863 · 10% owner Halak Brian K · CIK 0001354718 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 813,433 F1 · price: The reported securities were purchased as Units, each Unit consisting of one share of Common Stock and a Warrant to purchase 0.75 of one share of Common Stock, at a purchase price of $4.00 per Unit. F2 · balance_after: The reported ownership reflects the one-for-ten reverse split of the Common Stock effected on July 24, 2019. F3 · ownership.direct: The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of One Palmer Square Associates VII, LLC, the sole general partner of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her. F4 · ownership.direct: As managing members of One Palmer Square Associates VII, LLC, which is also the sole general partner of DP VII Associates, L.P., each Reporting Owner listed below may also be deemed to indirectly beneficially own 4,957 shares of Common Stock held by DP VII Associates, L.P. Read SEC document
May 29, 2019 Filed May 31, 2019 22:09 UTC	Esperion Therapeutics, Inc. ESPR · Entity 30796	GrantCommon Stock	4,967	$0.00	$0.00	Disclosure SEC source: 0000904454-19-000452 · edgar.xml · nonDerivative · entry 1 VITULLO NICOLE · CIK 0001196863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,286 F1 · shares: Represents restricted stock units, which vest in full on the earlier of (i) May 29, 2020 or (ii) the Issuer's next annual meeting of stockholders following May 29, 2019. Read SEC document
March 21, 2019 Filed Mar 21, 2019 13:02 UTC	Esperion Therapeutics, Inc. ESPR · Entity 30796	OtherCommon Stock	1,356	$0.00	$0.00	Disclosure SEC source: 0000904454-19-000335 · edgar.xml · nonDerivative · entry 6 VITULLO NICOLE · CIK 0001196863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,319 F5 · kind: Distribution of shares by One Palmer Square Associates VII, LLC pro rata to its members. F5 · price: Distribution of shares by One Palmer Square Associates VII, LLC pro rata to its members. Read SEC document
March 21, 2019 Filed Mar 21, 2019 13:02 UTC	Esperion Therapeutics, Inc. ESPR · Entity 30796	OtherCommon Stock	17,790	$0.00	$0.00	Disclosure SEC source: 0000904454-19-000335 · edgar.xml · nonDerivative · entry 5 VITULLO NICOLE · CIK 0001196863 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By One Palmer Square Associates VII, LLC Disclosed balance after: 0 F5 · kind: Distribution of shares by One Palmer Square Associates VII, LLC pro rata to its members. F5 · price: Distribution of shares by One Palmer Square Associates VII, LLC pro rata to its members. F2 · ownership.nature: The Reporting Person is a managing member of One Palmer Square Associates VII, LLC, the sole general partner of Domain Partners VII, L.P. Pursuant to Instruction 4(b)(iv) of Form 4, the Reporting Person has elected to report as indirectly beneficially owned the entire number of securities owned by each such entity, however she disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed her pecuniary interest therein and/or that are not actually distributed to her. Read SEC document
March 19, 2019 Filed Mar 21, 2019 13:02 UTC	Esperion Therapeutics, Inc. ESPR · Entity 30796	SaleCommon Stock	1,700	$45.25	$76,925.00	Disclosure SEC source: 0000904454-19-000335 · edgar.xml · nonDerivative · entry 4 VITULLO NICOLE · CIK 0001196863 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By DP VII Associates, L.P. Disclosed balance after: 0 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.16 to $45.34. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2 · ownership.nature: The Reporting Person is a managing member of One Palmer Square Associates VII, LLC, the sole general partner of Domain Partners VII, L.P. Pursuant to Instruction 4(b)(iv) of Form 4, the Reporting Person has elected to report as indirectly beneficially owned the entire number of securities owned by each such entity, however she disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed her pecuniary interest therein and/or that are not actually distributed to her. Read SEC document
March 19, 2019 Filed Mar 21, 2019 13:02 UTC	Esperion Therapeutics, Inc. ESPR · Entity 30796	SaleCommon Stock	13,629	$44.66	$608,671.14	Disclosure SEC source: 0000904454-19-000335 · edgar.xml · nonDerivative · entry 3 VITULLO NICOLE · CIK 0001196863 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By DP VII Associates, L.P. Disclosed balance after: 1,700 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.16 to $45.15. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2 · ownership.nature: The Reporting Person is a managing member of One Palmer Square Associates VII, LLC, the sole general partner of Domain Partners VII, L.P. Pursuant to Instruction 4(b)(iv) of Form 4, the Reporting Person has elected to report as indirectly beneficially owned the entire number of securities owned by each such entity, however she disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed her pecuniary interest therein and/or that are not actually distributed to her. Read SEC document
March 19, 2019 Filed Mar 21, 2019 13:02 UTC	Esperion Therapeutics, Inc. ESPR · Entity 30796	OtherCommon Stock	17,790	$0.00	$0.00	Disclosure SEC source: 0000904454-19-000335 · edgar.xml · nonDerivative · entry 2 VITULLO NICOLE · CIK 0001196863 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By One Palmer Square Associates VII, LLC Disclosed balance after: 17,790 F1 · kind: Distribution of shares by Domain Partners VII, L.P. pro rata to its partners. F1 · price: Distribution of shares by Domain Partners VII, L.P. pro rata to its partners. F2 · ownership.nature: The Reporting Person is a managing member of One Palmer Square Associates VII, LLC, the sole general partner of Domain Partners VII, L.P. Pursuant to Instruction 4(b)(iv) of Form 4, the Reporting Person has elected to report as indirectly beneficially owned the entire number of securities owned by each such entity, however she disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed her pecuniary interest therein and/or that are not actually distributed to her. Read SEC document
March 19, 2019 Filed Mar 21, 2019 13:02 UTC	Esperion Therapeutics, Inc. ESPR · Entity 30796	OtherCommon Stock	1,101,080	$0.00	$0.00	Disclosure SEC source: 0000904454-19-000335 · edgar.xml · nonDerivative · entry 1 VITULLO NICOLE · CIK 0001196863 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Domain Partners VII, L.P. Disclosed balance after: 0 F1 · kind: Distribution of shares by Domain Partners VII, L.P. pro rata to its partners. F1 · price: Distribution of shares by Domain Partners VII, L.P. pro rata to its partners. F2 · ownership.nature: The Reporting Person is a managing member of One Palmer Square Associates VII, LLC, the sole general partner of Domain Partners VII, L.P. Pursuant to Instruction 4(b)(iv) of Form 4, the Reporting Person has elected to report as indirectly beneficially owned the entire number of securities owned by each such entity, however she disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed her pecuniary interest therein and/or that are not actually distributed to her. Read SEC document
February 26, 2019 Filed Feb 28, 2019 17:21 UTC	MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359	GrantStock Option (Right to Buy) · Derivative	35,000	$0.00 Strike: $3.96	$0.00	Disclosure SEC source: 0000904454-19-000270 · edgar.xml · derivative · entry 1 VITULLO NICOLE · CIK 0001196863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2029-02-26 F1 · derivative.exercise_date: The option vests as to 5,833 shares immediately, and as to the remaining 29, 167 shares monthly over 10 months, beginning on 03/01/2019. Read SEC document
January 23, 2019 Filed Jan 25, 2019 16:30 UTC	ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234	GrantStock Option (Right to Buy) · Derivative	42,000	$0.00 Strike: $2.18	$0.00	Disclosure SEC source: 0000904454-19-000086 · edgar.xml · derivative · entry 1 VITULLO NICOLE · CIK 0001196863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,000 Underlying: Common Stock · 42,000 shares Expires 2029-01-23 F1 · derivative.exercise_date: The option vests in equal quarterly installments over the one-year period following the date of grant. Read SEC document
August 23, 2018 Filed Aug 27, 2018 17:32 UTC	Vyome Holdings, Inc OBLN · Entity 1824	PurchaseCommon Stock	1,648,359	$1.82	$3,000,013.38	Disclosure SEC source: 0000904454-18-000526 · edgar.xml · nonDerivative · entry 1 DOMAIN PARTERS VII L P · CIK 0001374150 · 10% owner BLAIR JAMES C · CIK 0001024000 · 10% owner DOVEY BRIAN H · CIK 0001207786 · 10% owner TREU JESSE I · CIK 0001013425 · 10% owner VITULLO NICOLE · CIK 0001196863 · 10% owner Halak Brian K · CIK 0001354718 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,634,329 F1 · ownership.direct: The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of One Palmer Square Associates VII, LLC, the sole general partner of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her. F2 · ownership.direct: As managing members of One Palmer Square Associates VII, LLC, which is also the sole general partner of DP VII Associates, L.P., each Reporting Owner listed below may also be deemed to indirectly beneficially own 49,908 shares of Common Stock held by DP VII Associates, L.P. Read SEC document
August 23, 2018 Filed Aug 27, 2018 17:20 UTC	Bionano Genomics, Inc. BNGO · Entity 7831	ConversionConvertible Promissory Note · Derivative	Not disclosed	$0.00 Strike: $4.59	$11,048.00	Disclosure SEC source: 0000904454-18-000524 · edgar.xml · derivative · entry 8 DP VIII Associates, L.P. · CIK 0001465143 · 10% owner BLAIR JAMES C · CIK 0001024000 · 10% owner DOVEY BRIAN H · CIK 0001207786 · 10% owner TREU JESSE I · CIK 0001013425 · 10% owner VITULLO NICOLE · CIK 0001196863 · 10% owner Halak Brian K · CIK 0001354718 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,505 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The principal amount of the Convertible Promissory Note held by the designated Reporting Person was $11,048. Upon closing of the IPO, all unpaid principal and accrued interest outstanding on the Convertible Promissory Note (the "Conversion Amount") automatically converted into the number of shares of Common Stock equal to the Conversion Amount as of the date immediately prior to the closing date divided by 75% of the IPO price per share of $6.125 per share. F3 · reported_value: The principal amount of the Convertible Promissory Note held by the designated Reporting Person was $11,048. Upon closing of the IPO, all unpaid principal and accrued interest outstanding on the Convertible Promissory Note (the "Conversion Amount") automatically converted into the number of shares of Common Stock equal to the Conversion Amount as of the date immediately prior to the closing date divided by 75% of the IPO price per share of $6.125 per share. F3 · derivative.exercise_date: The principal amount of the Convertible Promissory Note held by the designated Reporting Person was $11,048. Upon closing of the IPO, all unpaid principal and accrued interest outstanding on the Convertible Promissory Note (the "Conversion Amount") automatically converted into the number of shares of Common Stock equal to the Conversion Amount as of the date immediately prior to the closing date divided by 75% of the IPO price per share of $6.125 per share. F3 · derivative.expiration_date: The principal amount of the Convertible Promissory Note held by the designated Reporting Person was $11,048. Upon closing of the IPO, all unpaid principal and accrued interest outstanding on the Convertible Promissory Note (the "Conversion Amount") automatically converted into the number of shares of Common Stock equal to the Conversion Amount as of the date immediately prior to the closing date divided by 75% of the IPO price per share of $6.125 per share. F3 · derivative.underlying_shares: The principal amount of the Convertible Promissory Note held by the designated Reporting Person was $11,048. Upon closing of the IPO, all unpaid principal and accrued interest outstanding on the Convertible Promissory Note (the "Conversion Amount") automatically converted into the number of shares of Common Stock equal to the Conversion Amount as of the date immediately prior to the closing date divided by 75% of the IPO price per share of $6.125 per share. F2 · ownership.direct: The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of One Partner Square Associates VIII, LLC, the sole general partner of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her. Read SEC document
August 23, 2018 Filed Aug 27, 2018 17:20 UTC	Bionano Genomics, Inc. BNGO · Entity 7831	ConversionSeries D-1 Preferred Stock · Derivative	27,328	$0.00	$0.00	Disclosure SEC source: 0000904454-18-000524 · edgar.xml · derivative · entry 7 DP VIII Associates, L.P. · CIK 0001465143 · 10% owner BLAIR JAMES C · CIK 0001024000 · 10% owner DOVEY BRIAN H · CIK 0001207786 · 10% owner TREU JESSE I · CIK 0001013425 · 10% owner VITULLO NICOLE · CIK 0001196863 · 10% owner Halak Brian K · CIK 0001354718 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 638 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The Preferred Stock had no expiration date F1 · derivative.exercise_date: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The Preferred Stock had no expiration date F1 · derivative.expiration_date: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The Preferred Stock had no expiration date F2 · ownership.direct: The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of One Partner Square Associates VIII, LLC, the sole general partner of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her. Read SEC document
August 23, 2018 Filed Aug 27, 2018 17:20 UTC	Bionano Genomics, Inc. BNGO · Entity 7831	ConversionSeries D Preferred Stock · Derivative	47,460	$0.00	$0.00	Disclosure SEC source: 0000904454-18-000524 · edgar.xml · derivative · entry 6 DP VIII Associates, L.P. · CIK 0001465143 · 10% owner BLAIR JAMES C · CIK 0001024000 · 10% owner DOVEY BRIAN H · CIK 0001207786 · 10% owner TREU JESSE I · CIK 0001013425 · 10% owner VITULLO NICOLE · CIK 0001196863 · 10% owner Halak Brian K · CIK 0001354718 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,109 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The Preferred Stock had no expiration date F1 · derivative.exercise_date: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The Preferred Stock had no expiration date F1 · derivative.expiration_date: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The Preferred Stock had no expiration date F2 · ownership.direct: The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of One Partner Square Associates VIII, LLC, the sole general partner of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her. Read SEC document
August 23, 2018 Filed Aug 27, 2018 17:20 UTC	Bionano Genomics, Inc. BNGO · Entity 7831	ConversionSeries C Preferred Stock · Derivative	40,268	$0.00	$0.00	Disclosure SEC source: 0000904454-18-000524 · edgar.xml · derivative · entry 5 DP VIII Associates, L.P. · CIK 0001465143 · 10% owner BLAIR JAMES C · CIK 0001024000 · 10% owner DOVEY BRIAN H · CIK 0001207786 · 10% owner TREU JESSE I · CIK 0001013425 · 10% owner VITULLO NICOLE · CIK 0001196863 · 10% owner Halak Brian K · CIK 0001354718 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 941 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The Preferred Stock had no expiration date F1 · derivative.exercise_date: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The Preferred Stock had no expiration date F1 · derivative.expiration_date: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The Preferred Stock had no expiration date F2 · ownership.direct: The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of One Partner Square Associates VIII, LLC, the sole general partner of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her. Read SEC document
August 23, 2018 Filed Aug 27, 2018 17:20 UTC	Bionano Genomics, Inc. BNGO · Entity 7831	ConversionSeries B-1 Preferred Stock · Derivative	22,161	$0.00	$0.00	Disclosure SEC source: 0000904454-18-000524 · edgar.xml · derivative · entry 4 DP VIII Associates, L.P. · CIK 0001465143 · 10% owner BLAIR JAMES C · CIK 0001024000 · 10% owner DOVEY BRIAN H · CIK 0001207786 · 10% owner TREU JESSE I · CIK 0001013425 · 10% owner VITULLO NICOLE · CIK 0001196863 · 10% owner Halak Brian K · CIK 0001354718 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 518 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The Preferred Stock had no expiration date F1 · derivative.exercise_date: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The Preferred Stock had no expiration date F1 · derivative.expiration_date: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The Preferred Stock had no expiration date F2 · ownership.direct: The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of One Partner Square Associates VIII, LLC, the sole general partner of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her. Read SEC document
August 23, 2018 Filed Aug 27, 2018 17:20 UTC	Bionano Genomics, Inc. BNGO · Entity 7831	ConversionSeries B Preferred Stock · Derivative	50,532	$0.00	$0.00	Disclosure SEC source: 0000904454-18-000524 · edgar.xml · derivative · entry 3 DP VIII Associates, L.P. · CIK 0001465143 · 10% owner BLAIR JAMES C · CIK 0001024000 · 10% owner DOVEY BRIAN H · CIK 0001207786 · 10% owner TREU JESSE I · CIK 0001013425 · 10% owner VITULLO NICOLE · CIK 0001196863 · 10% owner Halak Brian K · CIK 0001354718 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,180 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The Preferred Stock had no expiration date F1 · derivative.exercise_date: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The Preferred Stock had no expiration date F1 · derivative.expiration_date: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The Preferred Stock had no expiration date F2 · ownership.direct: The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of One Partner Square Associates VIII, LLC, the sole general partner of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her. Read SEC document
August 23, 2018 Filed Aug 27, 2018 17:20 UTC	Bionano Genomics, Inc. BNGO · Entity 7831	ConversionCommon Stock	2,505	$4.59	$11,497.95	Disclosure SEC source: 0000904454-18-000524 · edgar.xml · nonDerivative · entry 2 DP VIII Associates, L.P. · CIK 0001465143 · 10% owner BLAIR JAMES C · CIK 0001024000 · 10% owner DOVEY BRIAN H · CIK 0001207786 · 10% owner TREU JESSE I · CIK 0001013425 · 10% owner VITULLO NICOLE · CIK 0001196863 · 10% owner Halak Brian K · CIK 0001354718 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,891 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: The principal amount of the Convertible Promissory Note held by the designated Reporting Person was $11,048. Upon closing of the IPO, all unpaid principal and accrued interest outstanding on the Convertible Promissory Note (the "Conversion Amount") automatically converted into the number of shares of Common Stock equal to the Conversion Amount as of the date immediately prior to the closing date divided by 75% of the IPO price per share of $6.125 per share. F2 · ownership.direct: The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of One Partner Square Associates VIII, LLC, the sole general partner of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her. Read SEC document
August 23, 2018 Filed Aug 27, 2018 17:20 UTC	Bionano Genomics, Inc. BNGO · Entity 7831	ConversionCommon Stock	4,386	Not disclosed	Not disclosed	Disclosure SEC source: 0000904454-18-000524 · edgar.xml · nonDerivative · entry 1 DP VIII Associates, L.P. · CIK 0001465143 · 10% owner BLAIR JAMES C · CIK 0001024000 · 10% owner DOVEY BRIAN H · CIK 0001207786 · 10% owner TREU JESSE I · CIK 0001013425 · 10% owner VITULLO NICOLE · CIK 0001196863 · 10% owner Halak Brian K · CIK 0001354718 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,386 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The Preferred Stock had no expiration date F2 · ownership.direct: The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of One Partner Square Associates VIII, LLC, the sole general partner of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.